WU-CART-007

Phase 2Cell therapy

WWugen, Inc.

WU-CART-007 is one of 52 biologic programs targeting T-cell acute lymphoblastic leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

T-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

63 competitors in T-Cell Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

7 2

Trexall

Alnylam Pharmaceuticals

Phase 3

6 3

Arranon

Novartis

Phase 3

6 4

Oncovin

Eli Lilly

Phase 3

5 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

7 6

Purinethol

SStason

Phase 3

4 7

Rayos

RRoxane Laboratories

Phase 3

3 8

Vepesid

AAvyxa

Phase 3

2 9

Oncovin

EEastern Cooperative Oncology Group

Phase 3

2 10

Ifex

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

T-Cell Acute Lymphoblastic Leukemia

NCT06514794

Clinical

Trials by Indication[1]

Hematologic Malignancies1 trial

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Active, not recruiting·WWashington University School of Medicine·Phase 1·NCT05377827·6 enrolled

T-cell acute lymphoblastic leukemia1 trial

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Recruiting·WWugen, Inc.·Phase 2·NCT06514794·125 enrolled

Relapsed or Refractory1 trial

A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

Completed·WWugen, Inc.·Phase 1·NCT04984356·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for WU-CART-007. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — WU-CART-007 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for WU-CART-007. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wugen, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: WWugen, Inc.

WU-CART-007

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Hematologic Malignancies1 trial

T-cell acute lymphoblastic leukemia1 trial

Relapsed or Refractory1 trial

References

Drug Info

Quick Facts

Related News